Histopathological biomarkers for nanomedicine-based cancer therapy

Researchers from the Institute of Experimental Molecular Imaging at RWTH Aachen University publish results on the identification of suitable tumor patients in clinical trials for nanoparticle-based cancer therapies.

Nanomedical formulations have attracted increasing public attention since the development of coronavirus vaccines. These formulations use a wide variety of drug carriers in the size range from 10 to 1000 nanometers to safely transport sensitive molecules such as mRNA to their target region. Over the years, drug carriers have already been developed to transport chemotherapeutic drugs into tumors in a more targeted manner and with fewer side effects. ...